Invea Therapeutics

Invea Therapeutics is a clinical-stage biotechnology company developing precision therapeutics for gastrointestinal (GI) and hepatobiliary disorders. Our unique approach targets the immune component of the gut-brain axis (GBA), which contributes to the resistance and partial response to existing therapies and leverages the power of AI and machine learning algorithms to decipher GBA biology. We discover programs at scale and with an increased probability of clinical and regulatory success.